



Canadian  
Institute  
of Actuaries

Institut  
canadien  
des actuaires

## Educational Note

# Guidance for the 2019 Valuation of Insurance Contract Liabilities of Life Insurers

Document 219093

**ARCHIVED**

**This document was archived April 11, 2023**

## ***Educational Note***

# **Guidance for the 2019 Valuation of Insurance Contract Liabilities of Life Insurers**

**Committee on Life Insurance Financial Reporting**

**ARCHIVED**

**August 2019**

Document 219093

*Ce document est disponible en français  
© 2019 Canadian Institute of Actuaries*

*The actuary should be familiar with relevant educational notes. They do not constitute standards of practice and are, therefore, not binding. They are, however, intended to illustrate the application of the Standards of Practice, so there should be no conflict between them. The actuary should note however that a practice that the educational notes describe for a situation is not necessarily the only accepted practice for that situation and is not necessarily accepted actuarial practice for a different situation. Responsibility for the manner of application of standards of practice in specific circumstances remains that of the members.*

## MEMORANDUM

**To:** Members in the Life Insurance Practice Area

**From:** Steven W. Easson, Chair  
Standards and Guidance Council

Marie-Andrée Boucher, Chair  
Committee on Life Insurance Financial Reporting

**Date:** August 28, 2019

**Subject:** **Educational Note: Guidance for the 2019 Valuation of Insurance Contract Liabilities of Life Insurers**

---

### Introduction

The purpose of this educational note is to provide guidance to actuaries in several areas affecting the valuation of the 2019 year-end insurance contract liabilities of life insurers for Canadian generally accepted accounting principles (GAAP) purposes. In addition, the note provides an update on recently published experience studies and introductory information about potential changes in future financial reporting. The guidance in this educational note represents a majority view of the members of the Committee on Life Insurance Financial Reporting (CLIFR) of appropriate practice consistent with the Standards of Practice.

In accordance with the Canadian Institute of Actuaries' (CIA) Policy on Due Process for the Approval of Guidance Material Other than Standards of Practice and Research Documents, this educational note has been prepared by CLIFR, and has received final approval for distribution by the Standards and Guidance Council on August 23, 2019.

The actuary should be familiar with relevant educational notes. They do not constitute standards of practice and are, therefore, not binding. They are, however, intended to illustrate the application of the Standards of Practice, so there should be no conflict between them. The actuary should note however that a practice that the educational notes describe for a situation is not necessarily the only accepted practice for that situation and is not necessarily accepted actuarial practice for a different situation. Responsibility for the manner of application of standards of practice in specific circumstances remains that of the members.

## Guidance to Members on Specific Situations

From time to time, CIA members seek advice or guidance from CLIFR. Both the CIA and CLIFR strongly encourage such dialogue. CIA members would be assured that it is proper and appropriate for them to consult with the chair or vice-chair of CLIFR.

CIA members are reminded that responses provided by CLIFR are intended to assist them in interpreting the CIA Standards of Practice, educational notes, and Rules of Professional Conduct, in assessing the appropriateness of certain techniques or assumptions. A response from CLIFR does not constitute a formal opinion as to whether the work in question is in compliance with the CIA Standards of Practice. Guidance provided by CLIFR is not binding upon the member.

## Recent Guidance

The following revisions to the Standards of Practice and related promulgations have been approved recently:

- [Final Communication of Updated Promulgations of the Ultimate Reinvestment Rates and Calibration Criteria for Stochastic Risk-Free Interest Rates to the Standards of Practice for the Valuation of Insurance Contract Liabilities: Life and Health \(Accident and Sickness\) Insurance \(Subsection 2330\)](#) (July 3, 2019);
- [Standards of Practice](#):
  - Revisions to Sections 1400 and 1500 of the General Standards pertaining to quality assurance (formerly peer review), effective July 1, 2019;
  - Addition of Subsection 3270 to the Pension-Specific Standards for Pensions pertaining to disclosure for stochastic models used to comply with specific regulatory pension plan funding requirements, effective July 1, 2019;
  - Revisions to the Practice-Specific Standards for Public Personal Injury Compensation Plans (Part 5000), effective December 15, 2019.
- Memorandum: [Revisions within the Practice-Specific Standards for Insurance \(Sections 2400 and 2500\)](#) (February 22, 2018);
- Final Standards – [Revisions within the Practice-Specific Standards for Insurance \(Sections 2400 and 2500\)](#) (February 22, 2018).

Recent CLIFR guidance includes the following material:

- Educational Note Supplement: [Calibration of Stochastic Risk-Free Interest Rate Models for Use in CALM Valuation](#) (April 2019);
- Explanatory report: [Development of the Ultimate Reinvestment Rates \(URRs\)](#) (June 2018);
- Educational Note: [Life Insurance Capital Adequacy Test \(LICAT\) and Capital Adequacy Requirements for Life and Health Insurance \(CARLI\)](#) (March 2018).

For your convenience all of these publications can be found on the CIA website under [Publications](#). A list of all the current educational notes and research papers can be found in appendix A.

Some guidance provided last year is still appropriate and has been duplicated in this educational note. The guidance is labelled as unchanged. Other guidance has been modified, either to

reflect recent developments or to improve clarity and is labelled as modified. The previous versions of this document can also be found in appendix A.

The topics covered herein are

1. Experience Studies ( <i>modified</i> ) .....	5
2. Life Insurance and Annuity Mortality ( <i>unchanged</i> ) .....	6
3. Accident and Sickness (A&S) Insurance Mortality and Morbidity ( <i>unchanged</i> ) .....	7
4. Economic Assumptions ( <i>modified</i> ) .....	7
5. International Financial Reporting Standards ( <i>modified</i> ) .....	10
6. Stochastic Scenarios ( <i>modified</i> ) .....	12
7. Capital Section ( <i>modified</i> ).....	13
Appendix A: CIA Guidance.....	14
Appendix B: NFI Assumption Capping Illustration .....	21

If you have any questions or comments regarding this educational note, please contact Marie-Andrée Boucher at [mboucher@eckler.ca](mailto:mboucher@eckler.ca).

SWE, MAB

ARCHIVED

## 1. Experience Studies (*modified*)

The Experience Research Committee (of the Research Council) has published the following studies since the beginning of 2018:

- Mortality study – [Canadian Standard Ordinary Life Experience 2015–2016 Using 86–92 and 97–04 Tables](#) (September 2018).

This report submitted by the Experience Research Subcommittee of the Canadian Institute of Actuaries (CIA) Research Council details the intercompany mortality experience for Canadian standard ordinary life insurance policies. It reflects the mortality experience of Canadian standard individual ordinary insurance issues between the 2015 and 2016 policy anniversaries.

- Mortality study – [Canadian Group Annuitant Mortality Experience, Calendar Years 2007–2016](#) (March 2019).

This is the second report of a study of experience for Canadian group annuitants with contributions from six companies. It covers the experience for calendar years 2007 to 2016. It includes the development of a new mortality table, GAC2012, based on the experience under study.

- Morbidity study – [Group Long-term Disability Termination Study](#) (January 2019).

This is the Phase 1 of the Group LTD study. Phase 1 is an updated study of Canadian Group Long-Term Disability termination tables based on recent experience for calendar years 2009 to 2015 with contributions from sixteen companies. Phase 2 – [Predictive Analytic Models for Canadian Group Disability Termination Experience](#) (May 2019) used the updated data from the phase 1 study and applied predictive analytics techniques to analyze the effects of approximately 15 variables.

- Morbidity study – [Canadian Individual Critical Illness Insurance Morbidity Experience Study Including Policy Anniversaries Between 2007 and 2016 Using Expected Incidence Rate Tables 2003 C-NCI](#) (June 2019).

This is the fourth report detailing the intercompany morbidity experience for Canadian individual critical illness (CI) insurance policies.

- Canadian Segregated Funds Product – [Canadian Segregated Funds Product Experience Study](#) (November 2018).

This report presents the results of a joint study conducted by the Society of Actuaries (SOA), LIMRA, and the Canadian Institute of Actuaries (CIA). The Segregated Fund study is the inaugural report presenting company mortality, surrender and withdrawal experience for Canadian segregated fund business with contributions from six companies.

The Experience Studies Research Subcommittee plans to publish the following studies in the future:

- Mortality study – Canadian Standard Ordinary Life Experience 2016–2017 Using 86–92 and 97–04 Tables.

This report reflects the mortality experience of Canadian standard individual ordinary insurance issues between the 2016 and 2017 policy anniversaries. This study is expected to be published later in 2019.

- Canadian Post-Level Term study

This is the first CIA study using predictive analytics to examine the lapse experience of term insurance policies once they reach their first renewal. It will also cover mortality experience. This study is expected to be published in early 2020.

## 2. Life Insurance and Annuity Mortality (*unchanged*)

On July 30, 2017, the Actuarial Standards Board (ASB) published a [Final Communication of a Promulgation of Prescribed Mortality Improvement Rates Referenced to the Standards of Practice for the Valuation of Insurance Contract Liabilities: Life and Health \(Accident and Sickness\) Insurance \(Subsection 2350\)](#) with an effective date of October 30, 2017.

This updated promulgation introduces new prescribed mortality improvement rates to be used in the calculation of the minimum valuation assumption, and the notion of diversification between death-sensitive and death-supported business. The new prescribed mortality improvement rates are a function of both the attained age and the calendar year. The promulgation also provides additional guidance on subsection 2350 on the definition of “appropriate level of aggregation” with regards to the impact of inclusion of mortality improvement in insurance contract liabilities, and on the application of mortality improvement rates for the calculation of accident and sickness insurance liabilities.

In addition, on May 17, 2017, the ASB Designated Group published a [Research Paper on Mortality Improvement Promulgation](#) that provides a rationale for the proposed mortality improvement rates of the updated promulgation. This paper references a final report prepared by the CIA [Task Force on Mortality Improvement](#) published in 2017. This report provides an analysis of the rate of mortality improvement for the Canadian population and the construction of a mortality projection scale for the purpose of reflecting future mortality improvement in Canadian actuarial work.

The actuary would be aware that mortality improvement is embedded in the CPM2014 and CIP2014 mortality tables, that adjusts the experience from the actual year up to 2014. The mortality improvement scale used in building these tables is the CPM-B scale. The actuary would consider if the use of these mortality tables without any adjustments is appropriate in the context of the most recent promulgation regarding mortality improvement.

The 2017 research paper did not comment specifically on the calculation of the best estimate expectation of life ( $e_x$ ). This calculation is relevant because it is a component of the life insurance margins for adverse deviations. Section 4.1 of the [Mortality Improvement Research Paper](#) published by CLIFR in September 2010 says that “The  $e_x$  component of the MfAD for the valuation of life insurance at attained age  $x$ , could be calculated as follows:”, then goes on to express a formula for  $e_x$  that includes a mortality improvement term applied to the  $q_x$  in the

projection. It then goes on to define the mortality improvement term as the “best estimate mortality improvement rate at age  $x+t$ ”. This guidance implies that  $e_x$  would be calculated using best estimate mortality improvement assumptions. CLIFR recommends that this methodology be applied when calculating  $e_x$ .

### 3. Accident and Sickness (A&S) Insurance Mortality and Morbidity (*unchanged*)

#### Mortality Improvement (*unchanged*)

The mortality improvement promulgation referred to in section 2 (Life Insurance and Annuity Mortality) also applies to A&S insurance, although the application varies by the status of the policyholder:

- **Active lives** (lives **not** currently receiving benefits and the portion of lives that are **not** expected to be in receipt of future benefits as measured in an active life reserve): the guidance provided in section 2 applies.
- **Non-active lives** (lives currently receiving benefits and the portion of lives that are expected to be in receipt of future benefits as measured in an active life reserve): the promulgation states that the actuary may consider reflecting mortality improvement; however, the minimum valuation assumption for mortality improvement does not apply to the valuation of these lives.

#### Morbidity Trends (*unchanged*)

In addition, the actuary may consider reflecting secular morbidity trends for accident and sickness insurance if the actuary has credible data or if the actuary has reliable benchmark data to use for purposes of projecting a morbidity trend. The data supporting longer-term trend assumptions would cover a relevant and sufficiently long period of experience to ascertain the secular trend and rule out shorter-term cyclical trends.

If a morbidity trend assumption is applied, then the actuary would apply a margin on the best estimate assumption consistent with subsection 2350 of the Standards of Practice. The actuary would consider whether the morbidity trend demonstrates unusually high uncertainty and would warrant selection of a margin above the high margin as noted in paragraph 2350.05 of the Standards of Practice. When assessing the appropriateness of aggregate provision for adverse deviations (PfAD) levels, actuaries would consider the interrelationships of the assumptions and any potential undesirable compounding of provisions.

### 4. Economic Assumptions (*modified*)

#### Credit Spreads (*unchanged*)

The revised educational note: [Investment Assumptions Used in the Valuation of Life and Health Insurance Contract Liabilities](#) (September 2015) provides guidance on developing assumptions for credit spreads, including margins and limits. Two clarifications follow:

- If testing at the level at which the Canadian asset liability method (CALM) liabilities are determined demonstrates that the promulgated maximum net credit spread after margin (net of defaults) increases the liabilities, then the additional margin pertaining to

the net credit spread after margin would be applied on each fixed-income asset. This is illustrated by the following example:

- The investment strategy in a given CALM segment assumes that reinvestment will be in three equally weighted fixed-income assets, with assumed ultimate net credit spreads after margin of 130 bps, 90 bps, and 50 bps respectively.
- The average net credit spread after margin, prior to the application of the paragraph 2330.08 additional margin is 90 bps.
- After application of the paragraph 2330.08 additional margin, the net credit spreads after margin for the first two assets are reduced to 80 bps each, and there is no change to the 50 bps assumption for the third asset. The resulting average net credit spread after margin is 70 bps.
- Additional scenarios (as defined in paragraph 2330.33) are limited to varying risk-free interest rates and not credit spreads.

In 2017, CLIFR formed a subcommittee to review the promulgated net credit spread. The mandate of the subcommittee was to update the data used by the pricing group for recent years, and assess if there is a need to recommend a change to the maximum of 80 bps promulgated in May 2014 ([Document 214046](#)). The working group's conclusion is that the change in historical spreads, after adding four years of data, is small and there is no evidence to support recommending a change to the promulgated maximum net credit spread of 80 bps.

#### **Ultimate Reinvestment Rate (*modified*)**

The ASB is responsible for promulgating the calibration criteria for stochastic risk-free interest rate models and the ultimate reinvestment rates (URRs) from time to time. The ongoing low interest rate environment has prompted the ASB to monitor these developments closely, and the ASB promulgated updated URRs and updated calibration criteria for year-end 2019. The [final promulgation](#) was published in July, and the effective date is October 15, 2019. The ASB does not anticipate an update to this promulgation prior to the adoption of IFRS 17. For further information on the calibration criteria, see section 6 below.

#### **Non-fixed Income (NFI) Returns Where Reliable Historical Information is not Available (*unchanged*)**

CLIFR formed a sub-committee in 2017 to provide additional guidance on setting the non-fixed income returns for the purpose of valuation, where reliable historical information is not available (as per paragraph 2340.18 of the Standards of Practice). More specifically, the sub-committee investigated the treatment of tax attributes in setting these assumptions and whether additional criteria for selecting benchmarks are necessary.

When setting investment return assumptions for non-fixed income (NFI) assets, the actuary would refer to the CIA Standards of Practice (SOP) and 2011 CLIFR educational note [Investment Return Assumptions for Non Fixed Income Assets for Life Insurers](#) (2011 educational note) for guidance. CLIFR was asked to review the existing guidance from two perspectives:

1. Assess whether the SOP and 2011 educational note provide sufficient criteria for determining appropriate benchmark indices, in situations where potential benchmarks exist.
2. Assess whether the SOP and 2011 educational note provide sufficiently clear guidance on capping the NFI return assumptions, in situations where reliable historical information does not exist.

CLIFR concluded, in consultation with the ASB, that no new guidance is necessary regarding the criteria for selecting appropriate benchmarks for NFI returns. However, additional guidance has been developed regarding the impact of taxes in the calculation of caps for assumed returns on NFI assets that lack reliable historical data. Both positions are explained below.

### **(1) Criteria for Benchmarks for NFI returns**

Paragraph 2340.15 of the SOP provides clear guidance that the NFI return assumption should not be more favourable than a benchmark based on historical performance of assets of its class and characteristics. The 2011 educational note provides further guidance on the meaning of “class and characteristics” and the time period over which the historical benchmark would be assessed. Furthermore, the 2011 educational note lists some specific benchmark indices that meet the criteria outlined in the SOP.

Use of the benchmark indices listed in the 2011 educational note would be appropriate without the need for justification if there is a clear linkage between the asset portfolio being modeled and the benchmark (e.g., if TSX is the index chosen to model the expected return on a diversified portfolio of Canadian equities). However, if the linkage is not clear, or if the chosen index is not listed in the 2011 educational note, then the actuary is reminded that it would be good practice to document how and why the chosen index is fit for purpose. Such documentation could include evidence of the following:

- The benchmark is viewed by a consensus of experts (internally and/or externally) as appropriate for the assets under consideration. In order to evidence the expert review, a formal report from the expert can be obtained which should include the expert’s opinion on choice of benchmark and the key elements of its suitability. In some circumstances, analysis is undertaken pertaining to the benchmark which would support the actuary’s choice of using it for valuation purposes. The actuary can use that information to support the choice of benchmark.
- The data underlying the benchmark has been validated for reliability.
- Caution should be exercised in removing data points where the removal of such data points results in a less prudent estimate of returns.

In order to use a benchmark the actuary must have confidence that it is fit for purpose and reliable.

### **(2) Capping NFI Assumptions where reliable historical information does not exist**

In situations where the actuary cannot show that a given index is fit for purpose, or where no reliable historical information exists for a given NFI asset, paragraph 2340.18 would

apply. That section of the Standards indicates that the actuary should cap the implied net risk premium inherent in the NFI return assumption at the net risk premium for assets of a similar class in (a) the same jurisdiction if reliable benchmarks are available in that jurisdiction, or (b) Canada, if reliable benchmarks are not available in that jurisdiction. If no similar asset class benchmark is available, then an appropriate equity benchmark should be used; the Canadian equity benchmark should be used if no reliable equity benchmark exists in the given jurisdiction.

The 2011 educational note provides a numerical example of how the net risk premium could be calculated. Neither paragraph 2340.18 nor the 2011 educational note specifically mention taxes. However, taxes could have a significant impact on market returns, especially in cases where a particular asset class receives tax-favoured treatment relative to other asset classes (e.g., dividends on Canadian equities). Furthermore, the general intent of the Standards is that the calculation of liabilities should comprise all cash flows in the term of the liability, including taxes.

CLIFR concluded that the example in the 2011 educational note should be enhanced to reflect taxes for comparisons of risk premiums between asset classes in the same jurisdiction, but that taxes need not be considered for comparisons of risk premiums between jurisdictions. This assessment is based on the theory that market participants would demand higher returns on non-tax-favoured assets relative to tax-favoured assets within the same jurisdiction, and therefore it would be appropriate to calibrate the corresponding net risk premiums, and more generally the impact on liabilities, on an after-tax basis. The relative after-tax return comparison becomes more complicated and perhaps less relevant for assets in different jurisdictions, hence CLIFR endorses the pre-tax comparison of net risk premiums in this situation.

Appendix B-1 repeats the example from the 2011 educational note, as it continues to be applicable when comparing risk premiums for a given asset class between Canada and a foreign jurisdiction. Appendix B-2 expands upon the 2011 educational note example, illustrating an after-tax net risk premium comparison within the same jurisdiction.

## **5. International Financial Reporting Standards (*modified*)**

### **IFRS 17 (*modified*)**

In May 2017, the International Accounting Standards Board (IASB) published the final standards for Insurance Contracts, IFRS 17. The implementation date is expected to be fiscal years beginning on or after January 1, 2022. For the most current information please see the [IASB website](#). Note that an eIFRS professional account is required to access the final standards and related documents.

The ASB Designated Group on Insurance Contract Standards of Practice, published the following document in May 2018: [Exposure Draft – Incorporate changes required by the adoption in Canada of IFRS 17 Insurance Contracts, including Principles of International Standard of Actuarial Practice 4 – Actuarial Practice in Relation to IFRS 17 Insurance Contracts, into the Canadian Standards of Practice](#). The Canadian Accounting Standards Board has indicated its intention that, once adopted by the IASB, and subject to its due process, IFRS 17 will be adopted

without modification for the valuation of insurance contracts in Canadian generally accepted accounting principles (GAAP) financial statements. The [International Actuarial Association](#) (IAA) released its second Exposure Draft of Proposed International Standard of Actuarial Practice 4 (ISAP 4) on IFRS 17 Insurance Contracts in February 2019. ISAP 4 covers actuarial practice in support of valuation of insurance contract liabilities in accordance with IFRS 17. The changes proposed in the CIA exposure draft align the SOP with the requirements of IFRS 17 and incorporate the guidance of ISAP 4. These developments require changes to the Canadian SOP, as the valuation methods under IFRS 17 are significantly different from the current methods of valuation of insurance contracts in Canada.

The CIA is very active in this area, with several committees involved in reviewing the IFRS 17 standard and related guidance.

The CIA Committee on International Insurance Accounting (IIAC) under the International Affairs Council has the following mandate with regards to international accounting and actuarial standards for the valuation of insurance and related products:

- Monitor developments and ensure that news of relevant and material developments is dispersed appropriately within the CIA;
- Recommend where specific additional Canadian guidance may be helpful, and if so, assist in its development; and
- Where relevant and appropriate, provide input from a CIA perspective to the international governing bodies.

The CIA Standards and Guidance Council (SGC) recently released the following two educational notes drafted by IIAC:

- [Transition from CALM to IFRS 17 Valuation of Canadian Participating Insurance Contracts](#) identifying the key components involved in the valuation of participating contracts, and how those components might change under the IFRS 17 framework compared to the current CALM framework, which was published in draft form in March 2019;
- [Comparison of IFRS 17 to Current CIA Standards of Practice](#) highlighting the key differences between CALM and IFRS 17, which was published in draft form in September 2018.

The IAA is developing an International Actuarial Note (IAN 100). The SGC has reviewed the current exposure draft of IAN 100 and released it as a draft educational note [Application of IFRS 17 Insurance Contracts](#) in February 2019. This note is intended to assist CIA members in the application of IFRS 17.

CLIFR will propose additional guidance to the members as needed, in the form of educational notes and reports. The guiding principles are:

- First and foremost, consider Canadian-specific perspectives, rather than simply repeating international actuarial guidance.
- Provide application guidance that is consistent with the IFRS 17 Standard and applicable Canadian actuarial Standards of Practice and educational notes, without unnecessarily narrowing the choices available in the IFRS 17 Standard.

- Consider practical implications associated with implementation of potential methods; in particular, ensure that due consideration is given to options that do not require undue cost and effort to implement.

CLIFR has formed subcommittees to look at the following topics:

- Estimates of Future Cash Flows;
- Discount Rate;
- Risk Adjustment for Non-Financial Risk;
- Coverage Units;
- Market Consistent Valuation of Financial Guarantees;
- Participating Products; and
- Investment Components and Embedded Derivatives.

The [IFRS 17 Risk Adjustment for Non-Financial Risk for Life and Health Insurance Contracts](#) draft educational note has already been published. The other educational notes identified are expected to be published in the coming months. After having reviewed the IFRS 17 Standards and existing guidance, including guidance from the IIAC and the IAA, the Investment Components and Embedded Derivatives subcommittee concluded that any Canadian-specific additional guidance was not needed at this time. The subcommittee will continue to monitor developments and coordinate guidance, as needed.

The CIA is also engaged in educating members about IFRS 17, through webcasts, sessions at CIA meetings, and other forums. The CIA website has an [IFRS blog](#) (you must log in to view the page). This members-only resource center serves as a repository for everything about IFRS 17, including documents, links to important websites, and updates from the committees working to help members for this significant change. Moreover, the mandates of each of the subcommittees mentioned above can be found on the blog.

### **IFRS 9 (slightly modified)**

Many insurers will not adopt IFRS 9 until IFRS 17 becomes effective in 2022. However, some entities have already adopted, most notably those that are part of larger financial institutions, such as bank-owned insurers. For those entities, the actuary could have seen changes in the carrying value of assets that potentially affected the CALM valuation. There could also have been new credit loss provisions established by the accountants under IFRS 9; if so, the actuary would have taken steps to avoid any double-counting with the credit provisions included in the CALM liability.

## **6. Stochastic Scenarios (modified)**

### **Calibration Criteria for Risk-Free Interest Rate Models Used in CALM Valuation (modified)**

CLIFR created a working group in 2018 to update the calibration criteria for stochastic risk-free interest rate models, and published a revised [educational note supplement](#) on April 18, 2019. The ASB's [final promulgation](#) of recommendations from this paper occurred on July 3, 2019 and has an effective date of October 15, 2019.

Included in the educational note supplement are updates to the guidance for the long-term (term to maturity of 20 years and longer) risk-free interest rate and for the short-term (one-year maturity) risk-free interest rate, medium-term (five- to 10-year maturity) risk-free interest rates, and the slope of the yield curve. The previous exercise considered data to mid-year 2016; the current group updated data to mid-year 2018, but otherwise preserved the methodology applied in the previous educational note supplement from 2017.

### **7. Capital Section (*modified*)**

Starting this year, the Committee on Risk Management and Capital Requirements (CRMCR) has launched a similar annual educational note that covers updates relevant for capital and risk management purposes, including updates to guidelines and/or CIA guidance on LICAT, dynamic capital adequacy testing (DCAT) and ORSA. This educational note includes links to relevant capital educational notes, regulatory guidelines and other useful references. The draft version has been circulated to various committees and the Standards and Guidance Council for review, targeting completion by September 2019.

ARCHIVED

**Appendix A: CIA Guidance**

Accession Number	Title	Publication Date
<b>General Standards</b>		
219058	Final Standards: <a href="#">Revisions to Sections 1400 and 1500 of General Standards of Practice (Part 1000)</a>	May 13, 2019
219057	Memorandum: <a href="#">Revisions to Sections 1400 and 1500 of General Standards of Practice (Part 1000)</a>	May 13, 2019
218076	<a href="#">Exposure draft to incorporate changes required by the adoption in Canada of IFRS 17 Insurance Contracts, including Principles of International Standard of Actuarial Practice 4 – Actuarial Practice in Relation to IFRS 17 Insurance Contracts, into the Canadian Standards of Practice</a>	May 16, 2018
218023	Final Standards: <a href="#">Revisions within the Practice-Specific Standards for Insurance (Sections 2400 and 2500)</a>	February 22, 2018
218024	Memorandum: <a href="#">Revisions within the Practice-Specific Standards for Insurance (Sections 2400 and 2500)</a>	February 22, 2018
217125	Final Standards: <a href="#">General (Part 1000)</a>	December 12, 2017
217126	Memorandum: <a href="#">Final Standard – Revisions to General Standards (Part 1000)</a>	December 12, 2017
217015	Memorandum: <a href="#">Revisions to the Practice-Specific Standards for Insurance (Part 2000)</a>	February 3, 2017
217014	Final Standards: <a href="#">Practice-Specific Standards for Insurance (Part 2000)</a>	February 3, 2017
217007	Educational Note: <a href="#">Use of Models</a>	January 26, 2017
217005	Final Standards: <a href="#">Revisions to General Standards to Reflect the Use of Models</a>	January 26, 2017
217006	Memorandum: <a href="#">Final Standards – Revisions to General Standards to Reflect the Use of Models</a>	January 26, 2017
214128	Memorandum: <a href="#">Final Standards – Revisions to the General and Practice-Specific Standards – Consistency of Reporting and Conformance with International Standard of Actuarial Practice 1</a>	December 9, 2014
214129	Final Standards: <a href="#">Revisions to the General and Practice-Specific Standards – Consistency of Reporting and Conformance with International Standard of Actuarial Practice 1</a>	December 9, 2014
213008	<a href="#">Final Standards for Practice-Specific Standards on Insurance Contract Valuation (Section 2300) to Narrow the Range of Practice on Certain Elements</a>	February 12, 2013

Accession Number	Title	Publication Date
211091	Final Standards of Practice: <a href="#">Standards of Practice for Recognizing Events in Work</a> (clean version)	September 26, 2011
210088	Research Paper: <a href="#">IFRS Disclosure Requirements for Life Insurers</a>	December 13, 2010
210086	Educational Note: <a href="#">Valuation of Gross Policy Liabilities and Reinsurance Recoverables</a>	December 1, 2010
206147	Educational Note: <a href="#">Use of Actuarial Judgment in Setting Assumptions and Margins for Adverse Deviations</a>	November 30, 2006
206132	Educational Note: <a href="#">Margins for Adverse Deviations</a>	November 8, 2006
205122	Educational Note: <a href="#">Applicability of Rules, Standards, and Other Guidance to CIA Members</a>	November 30, 2005
20169	Research Paper: <a href="#">Use of Stochastic Techniques to Value Actuarial Liabilities Under Canadian GAAP</a>	August 15, 2001
<b>Economic and CALM</b>		
219078	<a href="#">Final Communication of Updated Promulgations of the Ultimate Reinvestment Rates and Calibration Criteria for Stochastic Risk-Free Interest Rates in the Standards of Practice for the Valuation of Insurance Contract Liabilities: Life and Health (Accident and Sickness) Insurance (Subsection 2330)</a>	July 3, 2019
219046	Educational Note Supplement: <a href="#">Calibration of Stochastic Risk-Free Interest Rate Models for Use in CALM Valuation</a>	April 18, 2019
218091	Explanatory Report: <a href="#">Development of the Ultimate Reinvestment Rates</a>	June 26, 2018
218033	Educational Note: <a href="#">Life Insurance Capital Adequacy Test (LICAT) and Capital Adequacy Requirements for Life and Health Insurance (CARLI)</a>	March 14, 2018
217085	Revised Educational Note Supplement: <a href="#">Calibration of Stochastic Risk-Free Interest Rate Models for Use in CALM Valuation</a>	August 16, 2017
217081	<a href="#">Final Communication of Updated Promulgations of the Ultimate Reinvestment Rates and Calibration Criteria for Stochastic Risk-Free Interest Rates in the Standards of Practice for the Valuation of Insurance Contract Liabilities: Life and Health (Accident and Sickness) Insurance (Subsection 2330)</a>	July 30, 2017

Accession Number	Title	Publication Date
217080	<a href="#">Final Communication of a Promulgation of Calibration Criteria for Equity Investment Returns Referenced in the Standards of Practice for the Valuation of Insurance Contract Liabilities: Life and Health (Accident and Sickness) Insurance (Subsection 2370)</a>	July 28, 2017
217055	Research Paper: <a href="#">Calibration of Equity Returns and Volatility for Stochastic Models</a>	May 17, 2017
215111	Educational Note Supplement: <a href="#">Development of the Equilibrium Risk-Free Market Curve for the Base Scenario</a>	December 17, 2015
215111T	Educational Note Supplement: <a href="#">Development of the Equilibrium Risk-Free Market Curve for the Base Scenario: Excel File</a>	December 17, 2015
215072	Revised Educational Note: <a href="#">Investment Assumptions Used in the Valuation of Life and Health Insurance Contract Liabilities</a>	September 16, 2015
214109	Research Paper: <a href="#">Development of New Prescribed Interest Rate Scenarios for CALM Valuations</a>	October 10, 2014
214096	<a href="#">Final Communication of a Promulgation of Calibration Criteria for Investment Returns Referenced in the Standards of Practice for the Valuation of Insurance Contract Liabilities: Life and Health (Accident and Sickness) Insurance (Subsection 2360) (Fixed Income Returns)</a>	August 21, 2014
214046	<a href="#">Final Communication of Promulgations of the Maximum Net Credit Spread, Ultimate Reinvestment Rates, and Calibration Criteria for Stochastic Risk-Free Interest Rates in the Standards of Practice for the Valuation of Insurance Contract Liabilities: Life and Health (Accident and Sickness) Insurance (Subsection 2330 of the Final Standards for Revisions to the Standards of Practice)</a>	May 15, 2014
214047	Final Standards: <a href="#">Revisions to Economic Reinvestment Assumptions within the Practice-Specific Standards on Insurance Contract Valuation: Life and Health (Accident and Sickness) Insurance (Section 2300 and Subsection 1110)</a>	May 15, 2014
214048	Memorandum: <a href="#">Final Standards – Revisions to Economic Reinvestment Assumptions within the Practice-Specific Standards on Insurance Contract Valuation: Life and Health (Accident and Sickness) Insurance (Section 2300 and Subsection 1110)</a>	May 15, 2014
211027	Educational Note: <a href="#">Investment Return Assumptions for Non-Fixed Income Assets for Life Insurers</a>	March 1, 2011

Accession Number	Title	Publication Date
209121	Educational Note: <a href="#">Currency Risk in the Valuation of Policy Liabilities for Life and Health Insurers</a>	December 2, 2009
206133	Educational Note: <a href="#">Approximations to Canadian Asset Liability Method (CALM)</a>	November 8, 2006
206077	Educational Note: <a href="#">CALM Implications of AcSB Section 3855 Financial Instruments – Recognition and Measurement</a>	June 7, 2006
203106	Educational Note: <a href="#">Selection of Interest Rate Models</a>	December 2003
203083	Educational Note: <a href="#">Aggregation and Allocation of Policy Liabilities</a>	September 15, 2003
<b>Segregated Funds</b>		
214034	Research Paper: <a href="#">Calibration of Fixed-Income Returns for Segregated Fund Liability</a>	April 11, 2014
213004	Final Standards: <a href="#">Introduction of Standards relating to Appointed Actuary Opinions with Respect to Use of Internal Models to Determine Required Capital for Segregated Fund Guarantees</a>	February 7, 2013
212027	Educational Note: <a href="#">Reflection of Hedging in Segregated Fund Valuation</a>	May 10, 2012
210053	Report: <a href="#">Report of the Task Force on Segregated Fund Liability and Capital Methodologies</a>	August 11, 2010
207109	Educational Note: <a href="#">Considerations in the Valuation of Segregated Fund Products</a>	November 22, 2007
205111	Educational Note: <a href="#">Valuation of Segregated Fund Investment Guarantees (Revised)</a>	October 26, 2005
202012	Final Report: <a href="#">CIA Task Force on Segregated Fund Investment Guarantees</a>	March 6, 2002
<b>Universal Life</b>		
212012	Educational Note: <a href="#">Valuation of Universal Life Insurance Contract Liabilities</a>	February 28, 2012
<b>Mortality and Mortality Improvement</b>		
217097	<a href="#">Task Force Report on Mortality Improvement (Final)</a>	September 20, 2017
217097T	<a href="#">Task Force Report on Mortality Improvement (Final) – Excel File</a>	September 20, 2017

Accession Number	Title	Publication Date
217079	<a href="#">Final Communication of a Promulgation of Prescribed Mortality Improvement Rates and Associated Margins for Adverse Deviations within the Practice-Specific Standards on Insurance Contract Valuation: Life and Health (Accident and Sickness) Insurance (Subsection 2350) and the Accompanying Promulgation</a>	July 30, 2017
217079T	<a href="#">Final Communication of a Promulgation of Prescribed Mortality Improvement Rates and Associated Margins for Adverse Deviations within the Practice-Specific Standards on Insurance Contract Valuation: Life and Health (Accident and Sickness) Insurance (Subsection 2350) and the Accompanying Promulgation – Excel Workbook</a>	July 30, 2017
217054	<a href="#">Research Paper on Mortality Improvement Promulgation</a>	May 17, 2017
217054T	<a href="#">Research Paper on Mortality Improvement Promulgation – Excel File</a>	May 17, 2017
211070	Final Standards of Practice: <a href="#">Standards of Practice for the Valuation of Insurance Contract Liabilities: Life and Health (Accident and Sickness) Insurance (Subsection 2350) Relating to Mortality Improvement</a> (clean version)	July 12, 2011
210065	Research Paper: <a href="#">Mortality Improvement Research Paper</a>	September 23, 2010
202037	Educational Note: <a href="#">Expected Mortality: Fully Underwritten Canadian Individual Life Insurance Policies</a>	July 8, 2002
<b>Living Benefits</b>		
218034	Research Paper: <a href="#">Model of Long-Term Health Care Cost Trends in Canada</a>	March 14, 2018
<b>Group Life and Health</b>		
210069	Educational Note: <a href="#">Sources of Earnings Calculations – Group Life and Health</a>	October 7, 2010
210034	Educational Note: <a href="#">Valuation of Group Life and Health Policy Liabilities</a>	June 4, 2010
<b>Lapse</b>		
217019	Educational Note Supplement: <a href="#">Selective Lapsation for Renewable Term Insurance Products</a>	February 16, 2017

Accession Number	Title	Publication Date
217019t	Educational Note Supplement: <a href="#">Selective Lapsation for Renewable Term Insurance Products - Illustration of Methods</a>	February 16, 2017
<b>Par and Adjustable</b>		
214008	Educational Note: <a href="#">Dividend Determination for Participating Policies</a>	January 9, 2014
214006	Final Standards: <a href="#">Revocation of the Current Standards of Practice Entitled Recommendations – Dividend Determination and Illustration and Explanatory Notes in Amplification of Certain Dividend Recommendations, and Introduction of a New Subsection Relating to Participating Policy Dividend Determination in Part 2000 – Practice-Specific Standards for Insurance</a>	January 9, 2014
211123	Educational Note: <a href="#">Guidance on Fairness Opinions Required Under the Insurance Companies Act Pursuant to B-57 (2005)</a>	December 14, 2011
211084	Final Standards of Practice: <a href="#">Practice Specific Standards for Insurance, Incorporation of Standard Wording for Fairness Opinions (subsection 2460)</a>	September 7, 2011
<b>Tax and Expenses</b>		
212096	Educational Note: <a href="#">Future Income and Alternative Taxes</a>	December 17, 2012
208004	Educational Note: <a href="#">Implications of Proposed Revisions to Income Tax Legislation (May 7, 2007 Department of Finance Proposal)</a>	January 23, 2008
207029	Educational Note: <a href="#">Implications of CICA Handbook Section 3855 – Financial Instruments on Future Income and Alternative Taxes: Update to Fall Letter</a>	April 11, 2007
206134	Educational Note: <a href="#">Best Estimate Assumptions for Expenses</a>	November 8, 2006
<b>Guidance for the Valuation of Insurance Contract Liabilities of Life Insurers</b>		
218115	Educational Note: <a href="#">Guidance for the 2018 Valuation of Insurance Contract Liabilities of Life Insurers</a>	September 12, 2018
217098	Educational Note: <a href="#">Guidance for the 2017 Valuation of Insurance Contract Liabilities of Life Insurers</a>	September 20, 2017
216089	Educational Note: <a href="#">Guidance for the 2016 Valuation of Insurance Contract Liabilities of Life Insurers</a>	August 31, 2016

Accession Number	Title	Publication Date
<b>IFRS 17</b>		
219081	Draft Educational Note: <a href="#">IFRS 17 Risk Adjustment for Non-Financial Risk for Life and Health Insurance Contracts</a>	July 17, 2019
219036	Draft Educational Note: <a href="#">Transition from CALM to IFRS 17 Valuation of Canadian Participating Insurance Contracts</a>	March 27, 2019
219020	Draft Educational Not:- <a href="#">Application of IFRS 17 Insurance Contracts</a>	February 20, 2019
218117	Draft Educational Note: <a href="#">Comparison of IFRS 17 to Current CIA Standards of Practice</a>	September 13, 2018

ARCHIVED

Appendix B: NFI Assumption Capping Illustration

Appendix B-1: 2011 Ed Note example (pre-tax basis, relevant for comparison of foreign NFI asset vs Canadian benchmark for similar asset class)

Assumptions	Canada	Asset XYZ	XYZ Revised
<b>Historical Return</b>			
Capital Growth	9.50%	17.00%	14.08% <<- solve for yellow highlighted cell such that green highlighted cell equal to annualized net spread for Canada
Dividends	2.50%	3.00%	3.00%
<b>Total</b>	<b>12.00%</b>	<b>20.00%</b>	<b>17.08%</b>
<b>Risk Free Rate</b>			
Implied Spread	4%	6%	6%
	8.00%	200%	11.08%
<b>MFADs</b>			
Capital Growth	20%	20%	20%
Dividends	10%	20%	20%
Shock (years)	30%	40%	40%
<b>Assumed Growth (pre-tax, after MFAD)</b>			
Capital Growth	7.60%	13.60%	11.74%
Dividends	2.25%	2.40%	2.40%
<b>Total</b>	<b>9.85%</b>	<b>16.00%</b>	<b>13.66%</b>

  

Calculations	0	1	2	3	4	5	6	7	8	9	10	annualized net return	annualized risk free net spread	
Canada	1,000.00	1,096.50	1,206.70	1,325.56	1,456.13	1,119.69	1,229.98	1,351.17	1,484.72	1,630.42	1,791.01	6.00%	4%	2.00%
XYZ	1,000.00	1,160.00	1,345.60	1,560.90	1,810.64	1,260.20	1,461.84	1,695.73	1,970.05	2,381.78	2,646.86	10.22%	6%	4.22%
XYZ Revised	1,000.00	1,136.64	1,291.95	1,466.48	1,666.14	1,138.32	1,293.86	1,470.85	1,671.67	1,900.44	2,159.64	8.00%	6%	2.00%

  

**Observations:**

- This example is a replication of the illustration in the 2011 Ed Note. None of the assumptions have been changed.
- The "Canada" column represents the returns on a comparable asset class in Canada with a reliable benchmark.
- The "XYZ" column represents the assumed returns on a NFI asset in a foreign jurisdiction (where no reliable benchmark for a similar asset class exists).
- The "XYZ Revised" column represents the adjusted assumed returns on the NFI asset, after calibrating the annualized net spread to the Canadian benchmark, ignoring taxes.
- The calculated annualized net returns in this example assume full reinvestment of dividends into the asset/benchmark (i.e. compound growth).
- In this example, the assumed holding period of asset XYZ is 10 years.
- In this example, the resulting adjusted assumed growth rate (pre-tax, after MFAD) of 13.66% exceeds the Canadian benchmark of 9.85% because the risk free rate in the foreign jurisdiction is higher than in Canada, and because the assumed shock MFAD on XYZ exceeds the shock MFAD on the Canadian benchmark. Had these been equivalent, then the resulting adjusted assumed growth rate would have matched the Canadian benchmark.

**Appendix B-2. 2011 Ed Note example, enhanced to include impact of taxes for comparison of Canadian NFI asset (without reliable historical information) to accepted Canadian NFI benchmark**

Assumptions	Canada	ABC	ABC Revised
Historical Return			
Capital Growth	9.50%	17.00%	9.88% <-- solve for yellow/highlighted cell such that green highlighted cell equal to annualized net spread for Canada
Dividends	2.50%	3.00%	3.00%
<b>Total</b>	<b>12.00%</b>	<b>20.00%</b>	<b>12.88%</b>
Risk Free Rate	4%	4%	4%
Implied Spread	8.00%	16.00%	8.88%
MfADs			
Capital Growth	20%	20%	20%
Dividends	10%	10%	10%
Shock (year 5)	30%	30%	30%
Assumed Growth (after-tax, after MfAD)			
Capital Growth	5.70%	10.20%	5.50%
Dividends	2.25%	2.03%	2.00%
<b>Total</b>	<b>7.95%</b>	<b>12.23%</b>	<b>7.95%</b>

ARCHIVED

Calculations:	0	1	2	3	4	5	6	7	8	9	10	after-tax annualized net return	after-tax risk free return	after-tax annualized net spread
Canada	1,000.00	1,079.50	1,165.32	1,257.96	1,357.97	1,436.10	1,526.42	1,629.17	1,737.42	1,842.17	1,942.79	1,665.44	3.00%	2.23%
ABC	1,000.00	1,122.25	1,259.45	1,413.41	1,586.20	1,379.59	1,548.24	1,737.42	1,949.17	2,188.31	2,455.83	9.40%	3.00%	6.40%
ABC Revised	1,000.00	1,079.50	1,165.32	1,257.96	1,357.97	1,436.10	1,526.42	1,629.17	1,737.42	1,842.17	1,942.79	1,665.44	3.00%	2.23%

- Observations:**
- The "Canada" column represents the returns on a Canadian benchmark for a similar asset class where reliable historical information does exist - no change from 2011 example
  - The "ABC" column represents the assumed returns on a NFI asset in a Canada (where no reliable historical information exists for the given asset)
  - The "ABC Revised" column represents the adjusted assumed returns on the NFI asset, after calibrating the annualized after-tax net spread to the Canadian benchmark
  - The Canadian benchmark is assumed to receive tax-favourable treatment (ie. zero tax rate on dividends), whereas asset ABC returns are fully taxable
  - In this example, the risk free rate applicable to ABC is the Canadian rate, and the MfADs are assumed to be the same as for the Canadian benchmark (to isolate the impact of the tax effect)
  - The calculated annualized net returns in this example assume full reinvestment of dividends into the asset/benchmark (ie. compound growth), similar to the 2011 Ed Note example
  - Similar to the 2011 Ed Note example, the assumed holding period of asset ABC is 10 years.
  - In this example, the resulting adjusted assumed growth rate (after-tax, after MfAD) for ABC of 7.95% is equal to the Canadian benchmark of 7.95%.